Comparing Atorvastatin and Rosuvastatin's effects on Vitamin D levels in heart patients
Impact of Atorvastatin Versus Rosuvastatin on 25 Hydroxy Vitamin D Levels in Patients With Acute Coronary Syndrome
This study tests whether taking Atorvastatin or Rosuvastatin affects Vitamin D levels in heart patients with acute coronary syndrome.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Enrollment | 152 (estimated) |
| Ages | 18 Years to 65 Years |
| Sex | All |
| Sponsor | King Edward Medical University Academic / other |
| Locations | 1 site (Lahore, Punjab Province) |
| Trial ID | NCT06765265 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates the effects of Atorvastatin versus Rosuvastatin on Vitamin D levels in patients diagnosed with acute coronary syndrome. A total of 152 patients with normal Vitamin D levels will be randomly assigned to receive either Atorvastatin (40 mg/day) or Rosuvastatin (20 mg/day) for a duration of six months. The primary outcome will be the change in 25-hydroxy Vitamin D levels after the treatment period. This study aims to provide insights into the relationship between statin therapy and Vitamin D levels in this patient population.
Who should consider this trial
Good fit: Ideal candidates for this study are patients with acute coronary syndrome and 25 OH-Vitamin D levels between 30-70 ng/ml.
Not a fit: Patients with conditions such as hypercalcemia, pregnancy, or those who have used certain medications recently may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could help optimize treatment strategies for patients with acute coronary syndrome by improving their Vitamin D levels.
How similar studies have performed: While there is existing research on statins and Vitamin D, this specific comparison of Atorvastatin and Rosuvastatin in acute coronary syndrome patients is novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Acute Coronary Syndrome 25 OH-Vitamin D levels between 30-70ng/ml Exclusion Criteria: Hypercalcemia hypocalcemia pregnancy lactation hypersensitivity to statins hypothyroidism Deranged LFTs \& RFTs Use of following within last 3 months (Vitamin D Supplements, lipid lowering drugs, anti-obesity drugs, corticosteroids)
Where this trial is running
Lahore, Punjab Province
- King Edward Medical University — Lahore, Punjab Province, Pakistan (Recruiting)
Study contacts
- Principal investigator: Ali Hussnain — King Edward Medical University
- Study coordinator: Ali Hussnain
- Email: ahshah12@hotmail.com
- Phone: +923317641096
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.